Effect of Lidocaine Sprayed for Attenuating Hemodynamic Response During Laryngoscopy and Intubation
Launched by KHON KAEN UNIVERSITY · Jan 23, 2024
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how effective a medication called lidocaine is when sprayed directly into the throat area (laryngeal inlet) compared to lidocaine given through an IV (intravenous) line. The goal is to see which method better helps control heart rate and blood pressure during procedures where a tube is placed into the windpipe (intubation) in patients having brain surgery under general anesthesia. Researchers want to find out if the spray method is better at keeping these vital signs steady during the process.
To participate in this study, individuals need to be between 18 and 65 years old and in generally good health (classified as ASA I-II). However, those with certain conditions, such as allergies to lidocaine, difficult airways, or specific underlying health issues (like heart disease or severe kidney problems), will not be eligible. Participants will be randomly assigned to receive either the lidocaine spray or the IV lidocaine, and they can expect to be monitored closely during their procedure to see how well their body responds to each treatment method.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18-65 years old
- • 2. American Society of Anesthesiologists (ASA) physical status classification I-II
- Exclusion Criteria:
- • 1. History of lidocaine allergy
- • 2. Predicted difficult airways
- • 3. Body mass index \> 35 kilograms per meter squared
- • 4. Risk aspiration
- • 5. Baseline hemodynamic instability; heart rate \< 50 bpm, heart rate \> 120 bpm, blood pressure \< 90/60 mmHg, blood pressure \> 160/90 mmHg
- • 6. Underlying disease: epilepsy, cardiovascular disease, heart failure, impaired cardiac function, severe renal dysfunction, impaired hepatic function, peripheral vascular disease
- • 7. Pregnancy
- • 8. Cerebral aneurysm, Arteriovenous malformation, Tumor size \> 4 centimeters, Brain herniation
About Khon Kaen University
Khon Kaen University is a leading research institution in Thailand, dedicated to advancing medical science and improving healthcare outcomes through innovative clinical trials. With a commitment to ethical research practices and community health, the university collaborates with various national and international partners to conduct studies across diverse fields, including public health, pharmaceuticals, and medical devices. By leveraging its multidisciplinary expertise and state-of-the-art facilities, Khon Kaen University aims to contribute valuable insights and evidence-based solutions that address pressing health challenges both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nai Muang, Khonkaen, Thailand
Patients applied
Trial Officials
Nattawadee Phokaw, MD
Principal Investigator
Department of anesthesiologist, Faculty of Medicine, Khon Kaen University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported